BioNTech Price Target Maintained With a $171.00/Share by Canaccord Genuity

Dow JonesNov 18 22:37 · Ratings

BioNTech Is Maintained at Buy by Canaccord Genuity

Dow JonesNov 18 22:37 · Ratings

Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)

TipRanksNov 18 21:07 · Ratings

HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $150 Price Target

BenzingaNov 18 20:26 · Ratings

BioNTech Analyst Ratings

BenzingaNov 18 20:23 · Ratings

BioNTech SE: Strong Oncology Pipeline and Financial Position Offset Vaccine Business Uncertainty

TipRanksNov 18 19:45